Physician profile
Stuart Friedman
NPI 1679585715
$1,887.94
in general payments reported to CMS, 2019-2025
19 companies · $22.04 in 2025
The $22.04 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $105 · 2021: $334 · 2022: $1.10 · 2023: $315 · 2024: $644 · 2025: $22.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.05 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $344.88 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $342.06 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $154.38 | 2023-2024 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $151.10 | 2022-2024 | |
| Glaxosmithkline, LLC. | $129.80 | 2023-2024 | Jesduvroq, Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.56 | 2023-2024 | Jardiance |
| Ardelyx, INC. | $101.49 | 2024-2025 | Ibsrela |
| Amgen INC. | $88.80 | 2019-2021 | |
| Daiichi Sankyo INC. | $85.12 | 2019 | |
| Opko Pharmaceuticals, LLC | $85.03 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $75.81 | 2019 | |
| Horizon Therapeutics Plc | $50.53 | 2019-2021 | |
| Akebia Therapeutics INC | $33.67 | 2019-2024 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $25.46 | 2024 | Terlivaz |
| Fresenius USA Marketing, INC. | $24.36 | 2024 | Velphoro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $22.47 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.01 | 2021 | |
| Eisai INC. | $20.20 | 2020 | |
| Novo Nordisk INC | $17.21 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.